X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3412) 3412
Magazine Article (23) 23
Newsletter (15) 15
Book Chapter (8) 8
Newspaper Article (6) 6
Web Resource (4) 4
Publication (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2893) 2893
bupropion (1695) 1695
bupropion - therapeutic use (1617) 1617
male (1594) 1594
female (1551) 1551
adult (1307) 1307
psychiatry (1070) 1070
middle aged (1006) 1006
smoking cessation - methods (993) 993
pharmacology & pharmacy (920) 920
smoking cessation (877) 877
treatment outcome (767) 767
sustained-release bupropion (717) 717
smoking (605) 605
varenicline (605) 605
antidepressive agents, second-generation - therapeutic use (550) 550
nicotine (483) 483
double-blind (465) 465
dopamine uptake inhibitors - therapeutic use (452) 452
antidepressive agents - therapeutic use (414) 414
smoking cessation programs (411) 411
aged (410) 410
bupropion - adverse effects (410) 410
antidepressants (409) 409
nicotinic agonists - therapeutic use (404) 404
double-blind method (401) 401
adolescent (397) 397
neurosciences (388) 388
placebo (386) 386
receptor partial agonist (382) 382
substance abuse (376) 376
pharmacotherapy (375) 375
depression (359) 359
smoking-cessation (353) 353
cessation (347) 347
drug therapy (344) 344
animals (343) 343
bupropion - administration & dosage (335) 335
benzazepines - therapeutic use (323) 323
nicotine replacement therapy (321) 321
medicine, general & internal (320) 320
tobacco (317) 317
tobacco use disorder - drug therapy (317) 317
efficacy (313) 313
nicotine - therapeutic use (313) 313
quinoxalines - therapeutic use (303) 303
smokers (285) 285
drug therapy, combination (280) 280
depressive disorder - drug therapy (276) 276
smoking prevention (270) 270
research (264) 264
nicotine - administration & dosage (255) 255
psychology, clinical (255) 255
clinical neurology (251) 251
care and treatment (250) 250
young adult (249) 249
smoking - drug therapy (246) 246
bupropion - pharmacology (235) 235
analysis (227) 227
depressive disorder, major - drug therapy (223) 223
cigarette-smoking (219) 219
dose-response relationship, drug (219) 219
health aspects (217) 217
risk factors (216) 216
placebo-controlled trial (214) 214
randomized controlled-trial (214) 214
delayed-action preparations (210) 210
dependence (209) 209
clinical trials (205) 205
serotonin uptake inhibitors - therapeutic use (202) 202
usa (199) 199
smoking cessation - psychology (197) 197
dopamine (196) 196
public, environmental & occupational health (192) 192
randomized controlled trials as topic (187) 187
antidepressive agents, second-generation - adverse effects (185) 185
drugs (178) 178
therapy (175) 175
follow-up studies (174) 174
comorbidity (172) 172
counseling (167) 167
fluoxetine (165) 165
time factors (161) 161
smoking - epidemiology (160) 160
antidepressive agents - adverse effects (159) 159
medicine & public health (159) 159
major depression (158) 158
abridged index medicus (157) 157
smoking - psychology (157) 157
rats (153) 153
tobacco use disorder - therapy (152) 152
nicotine dependence (151) 151
pharmacology/toxicology (150) 150
clinical trials as topic (147) 147
antidepressant (146) 146
psychiatric status rating scales (146) 146
mental disorders (144) 144
pharmacology (144) 144
combined modality therapy (143) 143
controlled-trial (139) 139
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3345) 3345
Spanish (33) 33
French (32) 32
German (26) 26
Polish (9) 9
Dutch (7) 7
Japanese (5) 5
Portuguese (4) 4
Hungarian (3) 3
Norwegian (3) 3
Turkish (3) 3
Czech (2) 2
Hebrew (2) 2
Italian (2) 2
Chinese (1) 1
Finnish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 2016, Volume 2016, Issue 5, p. CD006103
Background Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract... 
Interventions to help smokers and other tobacco users to quit | Lungs & airways | Pharmacological interventions | Varenicline | Substance Withdrawal Syndrome | Azepines | Randomized Controlled Trials as Topic | Heterocyclic Compounds, 4 or More Rings | Alkaloids | Quinolizines | Tobacco, drugs & alcohol | By treatment type | Tobacco | Azocines | Bupropion | Benzazepines | Nicotinic Agonists | Counseling | Medications | Medicine General & Introductory Medical Sciences | Nicotine | Smoking | Smoking Cessation | Smoking [drug therapy] | Humans | RANDOMIZED CONTROLLED-TRIAL | Quinolizines [therapeutic use] | PSYCHIATRIC ADVERSE EVENTS | TOBACCO-DEPENDENCE TREATMENT | Quinoxalines [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Bupropion [therapeutic use] | Nicotine [adverse effects; antagonists & inhibitors] | REPLACEMENT THERAPY | SUSTAINED-RELEASE BUPROPION | Smoking Cessation [methods] | Counseling [methods] | VARENICLINE TREATMENT | METHADONE-MAINTAINED SMOKERS | Azepines [therapeutic use] | DOUBLE-BLIND PLACEBO | Alkaloids [therapeutic use] | Nicotinic Agonists [adverse effects; therapeutic use] | Azocines [therapeutic use] | LONG-TERM SAFETY | Benzazepines [therapeutic use] | PLACEBO-CONTROLLED TRIAL | Substance Withdrawal Syndrome [prevention & control] | Heterocyclic Compounds with 4 or More Rings [therapeutic use] | Quinolizines - therapeutic use | Azepines - adverse effects | Azocines - therapeutic use | Azocines - adverse effects | Substance Withdrawal Syndrome - prevention & control | Alkaloids - adverse effects | Benzazepines - adverse effects | Smoking - drug therapy | Heterocyclic Compounds, 4 or More Rings - adverse effects | Nicotinic Agonists - therapeutic use | Nicotine - antagonists & inhibitors | Smoking Cessation - methods | Azepines - therapeutic use | Nicotine - adverse effects | Nicotinic Agonists - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Benzazepines - therapeutic use | Counseling - methods | Alkaloids - therapeutic use | Quinolizines - adverse effects | Varenicline - therapeutic use | Bupropion - therapeutic use
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 4, Issue 4, p. CD006103
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 7, pp. 1765 - 1779
Journal Article
Expert Review of Neurotherapeutics, ISSN 1473-7175, 02/2016, Volume 16, Issue 2, pp. 131 - 144
Adult Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent psychiatric condition associated with high disability and frequent comorbidity. Current... 
Antidepressants | Attention Deficit Hyperactivity Disorder (ADHD) | Amphetamines | Efficacy | Lithium | Adults | Pharmacological Treatment | Metadoxine | ALZHEIMERS-DISEASE | BUPROPION TREATMENT | DEFICIT-HYPERACTIVITY DISORDER | CLINICAL NEUROLOGY | ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | MIXED AMPHETAMINE SALTS | RESPONSE-INHIBITION | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | LISDEXAMFETAMINE DIMESYLATE | RECEPTOR AGONIST | METADOXINE EXTENDED-RELEASE | Humans | Paroxetine - therapeutic use | Venlafaxine Hydrochloride - therapeutic use | Dopamine Agents - therapeutic use | Droxidopa - therapeutic use | Pyrrolidonecarboxylic Acid - therapeutic use | Adrenergic alpha-Agonists - therapeutic use | Histamine Agents - therapeutic use | Central Nervous System Stimulants - therapeutic use | Desipramine - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Pyridoxine - therapeutic use | Adult | Lobeline - therapeutic use | Benzhydryl Compounds - therapeutic use | Nomifensine - therapeutic use | Morpholines - therapeutic use | Bupropion - therapeutic use | Pyridines - therapeutic use | Wakefulness-Promoting Agents - therapeutic use | Duloxetine Hydrochloride - therapeutic use | Guanfacine - therapeutic use | Nicotinic Agonists - therapeutic use | Attention Deficit Disorder with Hyperactivity - drug therapy | Antidepressive Agents - therapeutic use | Mecamylamine - therapeutic use | Amphetamines - therapeutic use | Lithium Compounds - therapeutic use | Lisdexamfetamine Dimesylate - therapeutic use | Nicotinic Antagonists - therapeutic use | Quinazolinones - therapeutic use | Memantine - therapeutic use | Drug Combinations
Journal Article
Cochrane library, ISSN 1465-1858, 2013, Volume 2013, Issue 2, p. CD007253
Background Individuals with schizophrenia smoke more heavily than the general population and this contributes to their higher morbidity and mortality from... 
Interventions to help smokers and other tobacco users to quit | Lungs & airways | Tobacco Use Cessation Devices | Varenicline | Schizophrenia | Quinoxalines | Schizophrenic Psychology | Smoking Prevention | Interventions in specific groups | Randomized Controlled Trials as Topic | Tobacco, drugs & alcohol | For specific groups of smokers | Tobacco | Bupropion | Benzazepines | Nicotinic Agonists | Antidepressive Agents, Second‐Generation | Reinforcement, Psychology | Medicine General & Introductory Medical Sciences | Nicotine | Smoking Cessation | Humans | Reinforcement (Psychology) | Nicotine [administration & dosage] | SCHIZOAFFECTIVE DISORDER | VARENICLINE TREATMENT | RANDOMIZED CONTROLLED-TRIAL | Antidepressive Agents, Second-Generation [therapeutic use] | Smoking [prevention & control] | MEDICINE, GENERAL & INTERNAL | CIGARETTE-SMOKING | TRANSCRANIAL MAGNETIC STIMULATION | Bupropion [therapeutic use] | Nicotinic Agonists [administration & dosage] | DOUBLE-BLIND | Adult | PLACEBO-CONTROLLED TRIAL | TRANSDERMAL NICOTINE | SUSTAINED-RELEASE BUPROPION | ANTIPSYCHOTIC MEDICATIONS | Smoking Cessation [methods] | Nicotine - administration & dosage | Antidepressive Agents, Second-Generation - therapeutic use | Nicotinic Agonists - therapeutic use | Smoking Cessation - methods | Benzazepines - therapeutic use | Bupropion - therapeutic use | Quinoxalines - therapeutic use
Journal Article
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN 1469-493X, 2011, Issue 2, p. CD006103